Ann Lee
Known title: DirectorCIK: 0001953080
Ann Lee's purchase track record
Ann Lee has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/22/2023 | COYA | $4K | +41.3% | +129.6% | +13.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| COYA | ▲ Buy | Open Market | 1,000 | $4K | 8/22/2023 | View on chart |
| COYA | ▼ Sell | Other | 6,479 | $26K | 1/3/2023 | View on chart |
| COYA | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial
Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.